Search results
Results From The WOW.Com Content Network
Fetal warfarin syndrome appears in greater than 6% of children whose mothers took warfarin during pregnancy. [3] Warfarin has a low molecular weight so can pass from the maternal to fetal bloodstream through the tight filter-like junctions of the placental barrier. As the teratogenic effects of warfarin are well known, the medication is rarely ...
The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]
Warfarin (brand name Coumadin) is a commonly prescribed blood thinner both in the inpatient and outpatient hospital settings. In pregnant women, warfarin is contraindicated and should be avoided as it crosses the placental barrier. Additionally, warfarin is listed as Pregnancy Category D, which means it has a risk of harming the fetus. [37]
The main issue with anticoagulation in pregnancy is that warfarin, the most commonly used anticoagulant in chronic administration, is known to have teratogenic effects on the fetus if administered in early pregnancy. [11] [12] Still, there seems to be no teratogenic effect of warfarin before six weeks of gestation. [13]
Low molecular weight heparin (LMWH, such as enoxaparin) is generally used as an alternative. [44] Warfarin and LMWH may safely be used in breastfeeding. [44] When women experience recurrent pregnancy loss secondary to thrombophilia, some studies have suggested that low molecular weight heparin reduces the risk of miscarriage.
As they are administered by injection (intravenous, intramuscular or subcutaneous), they are less suitable for long-term treatment. [ 1 ] Argatroban (as well as the hirudins) is used for heparin-induced thrombocytopenia , a relatively infrequent yet serious complication of heparin treatment that requires anticoagulation (as it increases both ...
Use is not recommended during pregnancy or breastfeeding. [6] Compared to warfarin it has fewer interactions with other medications. [9] It is a direct thrombin inhibitor. [7] Dabigatran was approved for medical use in the United States in 2010. [6] It is on the World Health Organization's List of Essential Medicines. [10]
Average molecular weight: heparin is about 15 kDa, and LMWH is about 4.5 kDa. [25] Less frequent subcutaneous dosing than for heparin for postoperative prophylaxis of venous thromboembolism. Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high-dose heparin.